TY - JOUR T1 - Efficacy of Carboplatin and Paclitaxel with Bevacizumab as Salvage Chemotherapy for Non-small Cell Lung Cancer after Failure of Platinum-doublet Chemotherapy JF - Anticancer Research JO - Anticancer Res SP - 3553 LP - 3557 VL - 32 IS - 8 AU - MOTOHIRO TAMIYA AU - AKIHIRO TAMIYA AU - KEIKO NAKAO AU - KAZUHIRO ASAMI AU - KYOICHI OKISHIO AU - MORITA SATOMU AU - TAKAYUKI SHIROYAMA AU - NAOKO MORISHITA AU - HIDEKAZU SUZUKI AU - SHINJI SASADA AU - NORIO OKAMOTO AU - KYOICHI OKISHIO AU - TOMOYA KAWAGUCHI AU - MASASHI KOBAYASHI AU - SHINJI ATAGI AU - TOMONORI HIRASHIMA AU - ICHIRO KAWASE Y1 - 2012/08/01 UR - http://ar.iiarjournals.org/content/32/8/3553.abstract N2 - Background: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. Patient and Methods: Medical records of patients with non-squamous NSCLC who received CP plus BEV between November 2009 and September 2011 and experienced progression after at least one platinum-based-chemotherapy regimen, were examined in this retrospective study. Results: Twenty-one patients were eligible for this study. The median number of prior chemotherapy regimens was 3 (range, 2 to 9). The median number of cycles of CP with BEV was 4 (range, 1 to 6). Seven patients underwent BEV maintenance therapy, and the median number of cycles of BEV maintenance was 8 (range, 2 to 13). Toxicity levels were acceptable. The overall median survival time was not reached and one-year survival rate was 54.95%. The overall progression-free survival was 6.1 months (95% confidence interval, 4.4-9.3 months). Conclusion: CP with BEV was effective and feasible as a salvage chemotherapy after failure of platinum-based chemotherapy for patients with non-squamous NSCLC. ER -